MSK-Fusion

Overview

MSK-Fusion is an RNA anchored multiplex PCR panel used at Memorial Sloan Kettering Cancer Center for partner-agnostic detection of oncogenic gene fusions in tumor samples PMID:38922339.

Used by

• PMID:38922339 — MSK-Fusion was one of three sequencing platforms (alongside MSK-IMPACT and MSK-ACCESS) used to sequence 97,024 samples from 69,337 patients between January 2014 and November 2022 at MSK; identified 212 patients with oncogenic BRAF fusions across 52 histologies, with 82 unique 5’ fusion partners PMID:38922339.
• PMID:39753968 — MSK-Fusion (Archer FusionPlex RNA-based panel) was applied to 90 of 2,336 PAAD patients to detect actionable gene fusions; activating MAPK-pathway fusions were nearly exclusive to KRAS-WT tumors (3.2% vs 0.04%, P=2×10⁻³⁵); GIT2–BRAF and ATP1B1–NRG1 fusions identified in MAPK-WT tumors PMID:39753968.
• MSK-Solid Fusion targeted RNA panel using Archer FusionPlex Anchored Multiplex PCR over 35 rearranged genes, used for orthogonal RNA fusion confirmation in the MSK-IMPACT prospective cohort PMID:28481359

Notes

• Partner-agnostic RNA-based fusion detection is critical for identifying the extraordinary diversity of BRAF and other fusion partners PMID:38922339.
• Corpus-grown slug; not present in schema/ontology/gene_panels.json.

Sources

• PMID:38922339
• PMID:39753968

This page was processed by crosslinker on 2026-05-04. - PMID:28481359

This page was processed by wiki-cli on 2026-05-15.